Skip to main content

LEGN

Stock
Health Care
Biotechnology

Performance overview

LEGN Price
Price Chart

Forward-looking statistics

Beta
0.57
Risk
47.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$8.3B

Fundamentals

Enterprise value$12.4B
Revenue$728.3M
Revenue per employee—
Profit margin-29.95%
Debt to equity35.65

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$1.18
Dividend per share—
Revenue per share$3.97
Avg trading volume (30 day)$76M
Avg trading volume (10 day)$63M
Put-call ratio—

Macro factor sensitivity

Growth-0.8
Credit+3.2
Liquidity+0.9
Inflation-4.6
Commodities-1.7
Interest Rates-0.5

Valuation

Dividend yield0.00%
PEG Ratio-53.19
Price to sales9.01
P/E Ratio-53.19
Enterprise Value to Revenue17.05
Price to book6.44

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?

Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research (July 18, 2025)
Mizuho's Jared Holz details potential biotech, pharma acquisitions

Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.

CNBC Television (June 4, 2025)
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet

The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (May 2, 2025)
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

With U.S. President Donald Trump's tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertainty.

Benzinga (April 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free